Strategic Pivot: From Glucose to UTI & AMR – Summer 2024

In Summer 2024, DRUiD made a strategic decision to pivot its primary focus from glucose-based diagnostics for early Type 1 diabetes detection to the development of a rapid, at-home diagnostic for urinary tract infections (UTIs) with integrated antimicrobial resistance (AMR) profiling.

This shift reflects the urgent and growing clinical need for accessible tools that can guide accurate, early treatment of UTIs—one of the most common infections worldwide and a significant contributor to inappropriate antibiotic use.

While our glucose sensor technology remains under development, and the original vision for early Type 1 detection is still very much alive, this pivot allows us to apply our biosensing platform to an area where we can make immediate, scalable impact on human health.

By focusing on UTIs and AMR, we are aligning our work with public health priorities, regulatory momentum, and clinical demand—all while retaining the potential to return to glucose, female health and metabolic applications in the near future.

This decision positions DRUiD to deliver value faster—without losing sight of our long-term vision.